Tenax Therapeutics (TENX) Cash from Financing Activities (2010 - 2026)
Tenax Therapeutics recorded quarterly Cash from Financing Activities of $30.5 million in Q1 2026, up 162.67% quarter-over-quarter from $11.6 million in Q4 2025, and up 29.44% year-over-year from $23.6 million in Q1 2025.
Tenax Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at $30.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 29.44% year-over-year to $30.5 million; the TTM figure through Mar 2026 stood at $45.4 million (down 60.65% YoY), while the FY2025 annual figure was $38.5 million, down 61.44% from the prior year.
- Cash from Financing Activities came in at $30.5 million for Q1 2026 at Tenax Therapeutics, up from $11.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $92.0 million in Q3 2024 to a low of -$174603.0 in Q4 2023.
- A 5-year average of $11.2 million and a median of $278000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities sank 8563.55% in 2023 and soared 53820.45% in 2024, its largest moves.
- Tenax Therapeutics' Cash from Financing Activities stood at $2063.0 in 2022, then tumbled by 8563.55% to -$174603.0 in 2023, then surged by 138.37% to $67000.0 in 2024, then jumped by 17229.85% to $11.6 million in 2025, then soared by 162.67% to $30.5 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $30.5 million, $11.6 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | 30.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.50 Mn |
| Mar 31, 2026 | 30.50 Mn |
| Dec 31, 2025 | 11.61 Mn |
| Dec 31, 2025 | 11.61 Mn |
| Sep 30, 2025 | 3.06 Mn |
| Sep 30, 2025 | 3.06 Mn |
| Jun 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Mar 31, 2025 | 23.56 Mn |
| Mar 31, 2025 | 23.56 Mn |
| Dec 31, 2024 | 67,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Sep 30, 2024 | 92.01 Mn |
| Sep 30, 2024 | 92.01 Mn |
| Jun 30, 2024 | -134,000.00 |
| Jun 30, 2024 | -134,000.00 |
| Mar 31, 2024 | 7.92 Mn |
| Mar 31, 2024 | 7.92 Mn |
| Dec 31, 2023 | -174,603.00 |
| Dec 31, 2023 | -174,603.00 |
| Sep 30, 2023 | -171,283.00 |
| Sep 30, 2023 | -171,283.00 |
| Jun 30, 2023 | -99,907.00 |
| Jun 30, 2023 | -99,907.00 |
| Mar 31, 2023 | 14.01 Mn |
| Mar 31, 2023 | 14.01 Mn |
| Dec 31, 2022 | 2,063.00 |
| Dec 31, 2022 | 2,063.00 |
| Sep 30, 2022 | -91,875.00 |
| Sep 30, 2022 | -91,875.00 |
| Jun 30, 2022 | 7.79 Mn |
| Jun 30, 2022 | 7.79 Mn |
| Mar 31, 2022 | 228,762.00 |
| Mar 31, 2022 | 228,762.00 |
| Sep 30, 2021 | 9.19 Mn |
| Sep 30, 2021 | 9.19 Mn |
| Mar 31, 2021 | 544,651.00 |
| Mar 31, 2021 | 544,651.00 |
| Dec 31, 2020 | -1,351.00 |
| Dec 31, 2020 | -1,351.00 |
| Sep 30, 2020 | 6.53 Mn |
| Sep 30, 2020 | 6.53 Mn |
| Jun 30, 2020 | 1.94 Mn |
| Jun 30, 2020 | 1.94 Mn |
| Mar 31, 2020 | 2.13 Mn |
| Mar 31, 2020 | 2.13 Mn |
| Mar 31, 2019 | 96,500.00 |
| Mar 31, 2019 | 96,500.00 |
| Dec 31, 2018 | 8.91 Mn |
| Dec 31, 2018 | 8.91 Mn |
| Dec 31, 2015 | -100,160.00 |
| Dec 31, 2015 | -100,160.00 |
| Sep 30, 2015 | -48,209.00 |
| Sep 30, 2015 | -48,209.00 |
| Jun 30, 2015 | -298,988.00 |
| Jun 30, 2015 | -298,988.00 |
| Jul 31, 2014 | 196,437.00 |
| Jul 31, 2014 | 196,437.00 |
| Apr 30, 2014 | 54.99 Mn |
| Apr 30, 2014 | 54.99 Mn |
| Jan 31, 2014 | 6.55 Mn |
| Jan 31, 2014 | 6.55 Mn |
| Oct 31, 2013 | 518,838.00 |
| Oct 31, 2013 | 518,838.00 |
| Jul 31, 2013 | 4.89 Mn |
| Jul 31, 2013 | 4.89 Mn |
| Apr 30, 2013 | 1.44 Mn |
| Apr 30, 2013 | 1.44 Mn |
| Jan 31, 2013 | 91,462.00 |
| Jan 31, 2013 | 91,462.00 |
| Oct 31, 2012 | -14,027.00 |
| Oct 31, 2012 | -14,027.00 |
| Jul 31, 2012 | 2.46 Mn |
| Jul 31, 2012 | 2.46 Mn |
| Apr 30, 2012 | 73,224.00 |
| Apr 30, 2012 | 73,224.00 |
| Jan 31, 2012 | 3.60 Mn |
| Jan 31, 2012 | 3.60 Mn |
| Oct 31, 2011 | 610,550.00 |
| Oct 31, 2011 | 610,550.00 |
| Jul 31, 2011 | 5.19 Mn |
| Jul 31, 2011 | 5.19 Mn |
| Apr 30, 2011 | 2.27 Mn |
| Apr 30, 2011 | 2.27 Mn |
| Jan 31, 2011 | 2.06 Mn |
| Jan 31, 2011 | 2.06 Mn |
| Oct 31, 2010 | -19,936.00 |
| Oct 31, 2010 | -19,936.00 |
| Jul 31, 2010 | 4.87 Mn |
| Jul 31, 2010 | 4.87 Mn |